Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options.

Clinical pharmacology and therapeutics - 1 Mar 2019

Ference Brian A

Abstract excerpt

Mendelian randomization studies and "human knock-out" studies of rare loss-of-function coding variants suggest that plasma levels of low-density lipoprotein-cholesterol LDL-C, triglycerides (TGs), and lipoprotein(a) (Lp(a)) are causally associated with the risk of cardiovascular disease, and, therefore, therapies directed against these targets should reduce the risk of cardiovascular events. However, several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, HDL
Share to Cholesterol, LDL
Share to Drug Delivery Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Development

Share to Drug Discovery

Share to Forecasting

Share to Hypolipidemic Agents

Share to Mendelian Randomization Analysis

Source

Identifiers

PMID: 29953581
DOI: 10.1002/cpt.1163

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options.PMID 29953581Read ↗

Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.Semantic proximity Read ↗

Target Discovery for Drug Development Using Mendelian Randomization.Semantic proximity Read ↗

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.Semantic proximity Read ↗

Gene-based therapy in lipid management: the winding road from promise to practiceSemantic proximity Read ↗

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read ↗

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

Assessing long-term pleiotropic effects of potential novel triglyceride-lowering medications using variants identified by Mendelian randomizationSemantic proximity Read ↗

Common pitfalls in drug target Mendelian randomization and how to avoid them.Semantic proximity Read ↗

Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.